drugset / Trial / NCT05712876
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants and Otherwise Healthy Participants With Obesity
Phase 1
Completed
76 enrolled
Cytoki Pharma
SGS Life Sciences, a division of SGS Belgium NV · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to assess the safety, tolerability and blood levels following a single dose or after multiple doses of CK-0045 given subcutaneously to healthy participants or otherwise healthy participants with obesity. 76 participants will receive CK-0045 or matching placebo at different escalating doses in 2 study parts: 40 healthy participants will receive a single dose and 36 otherwise healthy participants with obesity will receive 6 doses one week apart.
Timeline
- Start
- 2022-12-26
- Primary completion
- 2024-01-04
- Completion
- 2024-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CK-0045 | Unknown | — | Subcutaneous |
Indications
No indication recorded.